Background Dual antithrombotic therapy (DAT) with clopidogrel and a novel oral
anticoagulant (NOAC) is the treatment of choice in patients undergoing PCI who require oral …

Background Among patients treated with a novel oral anticoagulant (NOAC) undergoing
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …

Introduction: Dual antiplatelet therapy (DAPT) and dual pathway inhibition (DPI) are
potential long-term antithrombotic strategies for patients with coronary artery disease (CAD) …

Background: Triple antithrombotic therapy is used in patients who require systemic
anticoagulation and undergo percutaneous coronary intervention (PCI) requiring dual …

Background Since the introduction of newer, more potent P2Y 12 receptor inhibitors (P2Y 12
ris), practice patterns and associated clinical outcomes in patients with myocardial infarction …

Dual anti-platelet therapy with aspirin and a P2Y12 inhibitor plays a key role in reducing
ischaemic complications in patients with acute coronary syndromes (ACSs) undergoing …

Objectives: The purpose of this study was to determine whether bleeding risk varies
depending on which P2Y12 receptor inhibitor agent is used. Background: Prior studies have …

Background Triple antithrombotic therapy, including dual antiplatelet therapy and oral
anticoagulant (OAC), is recommended for a short-term period after percutaneous coronary …

Finding the optimal antithrombotic therapy in patients undergoing percutaneous coronary
intervention (PCI) with an indication for long-term oral anticoagulants remains a challenge. 1 …

2 Arterioscler Thromb Vasc Biol April 2018 ticagrelor was superior to clopidogrel in> 18 000
patients with ACS (either STEMI or non-STEMI) undergoing PCI who were treated with …